CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. Hypersensitivity to any component of this medication ) 4 Active liver disease or unexplained, persistent elevations in serum transaminases , o 5.2 Women who are pregnant or may become pregnant , o 8.1 Nursing mothers , o 8.3 Hypersensitivity to any component of this medication ) 4 Active liver disease or unexplained, persistent elevations in serum transaminases , o 5.2 Women who are pregnant or may become pregnant , o 8.1 Nursing mothers , o 8.3 4.1 Hypersensitivity to Any Component of This Medication. Fluvastatin capsules are contraindicated in patients with hypersensitivity to any component of this medication.. 4.2 Active Liver Disease. Fluvastatin capsules are contraindicated in patients with active liver disease or unexplained, persistent elevations in serum transaminases. [See .] Warnings and Precautions (5.2) 4.3 Pregnancy. Fluvastatin capsules are contraindicated in women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Fluvastatin may cause fetal harm when administered to pregnant women. Atherosclerosis is chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia.Fluvastatin capsules should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this drug, fluvastatin capsules should be discontinued and the patient should be apprised of the potential hazard to the fetus. [See .] Use in Specific Populations (8.1) 4.4 Nursing Mothers. Fluvastatin is secreted into the breast milk of animals and because HMG-CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women who require treatment with fluvastatin capsules should be advised not to breast-feed their infants. [See .] Use in Specific Populations (8.3).

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following serious adverse reactions are discussed in greater detail in other sections of the label:Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including myositis) [see ]. Warnings and Precautions (5.1) Liver Enzyme Abnormalities [see ]. Warning and Precautions (5.2) Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including myositis) [see ]. Warnings and Precautions (5.1) Liver Enzyme Abnormalities [see ]. Warning and Precautions (5.2) Most frequent adverse reactions (rate >= 2% and placebo) are: headache, dyspepsia, myalgia, abdominal pain and nausea ) 6.1 To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. Most frequent adverse reactions (rate >= 2% and placebo) are: headache, dyspepsia, myalgia, abdominal pain and nausea ) 6.1 To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1 Clinical Studies Experience in Adult Patients. Because clinical studies on fluvastatin are conducted in varying study populations and study designs, the frequency of adverse reactions observed in the clinical studies of fluvastatin cannot be directly compared with that in the clinical studies of other statins and may not reflect the frequency of adverse reactions observed in clinical practice.In the fluvastatin capsules placebo-controlled clinical trials database of 2,326 patients treated with fluvastatin capsules (age range 18 to 75 years, 44% women, 94% Caucasians, 4% Blacks, 2% other ethnicities) with median treatment duration of 24 weeks, 3.4% of patients on fluvastatin and 2.3% patients on placebo discontinued due to adverse reactions regardless of causality. The most common adverse reactions that led to treatment discontinuation and occurred at an incidence greater than placebo were: transaminase increased (0.8%), upper abdominal pain (0.3%), dyspepsia (0.3%), fatigue (0.2%) and diarrhea (0.2%).Clinically relevant adverse experiences occurring in the fluvastatin capsules controlled studies with frequency >= 2%, regardless of causality, included the following:Table 1: Clinical Adverse Events Reported in >= 2% in Patients Treated with Fluvastatin Capsules and at an Incidence Greater than Placebo in Placebo-Controlled Trials Regardless of Causality (% of Patients) Pooled DosagesFluvastatin CapsulesControlled trials with fluvastatin capsules (20 mg and 40 mg daily and 40 mg twice daily) compared to placebo.N 2,326(%)PlaceboN 960(%)MusculoskeletalMyalgia54.5 Arthritis2.12 ArthropathyNANARespiratorySinusitis2.61.9 Bronchitis1.81GastrointestinalDyspepsia7.93.2 Diarrhea4.94.2 Abdominal Pain4.93.8 Nausea3.22 FlatulenceTooth Disorder2.62.12.51.7PsychiatricInsomnia2.71.4GenitourinaryUrinary Tract Infection1.61.1MiscellaneousHeadache8.97.8 Influenza-Like Symptoms5.15.7 Accidental Trauma5.14.8 Fatigue2.72.3 Allergy2.32.2. Fluvastatin Capsules Intervention Prevention Study. In the Fluvastatin Capsules Intervention Prevention Study, the effect of fluvastatin capsules 40 mg, administered twice daily on the risk of recurrent cardiac events was assessed in 1,677 patients with CHD who had undergone percutaneous coronary intervention (PCI) procedure. This was multicenter, randomized, double-blind, placebo-controlled study, patients were treated with dietary/lifestyle counseling and either fluvastatin capsules 40 mg (n 844) or placebo (n 833) given twice daily for median of 3.9 years [see Clinical Studies (14.3) Table 2: Clinical Adverse Events Reported in >= 2% in Patients Treated with Fluvastatin and at an Incidence Greater than Placebo in the Trial Regardless of Causality (% of Patients)Fluvastatin40 mg BIDN 822(%)PlaceboN 818(%)Cardiac DisordersAtrial Fibrillation2.42Gastrointestinal DisordersAbdominal Pain Upper6.34.5Constipation3.32.1Dyspepsia4.54Gastric Disorder2.72.1Nausea2.72.3General DisordersFatigue4.73.8Edema Peripheral4.42.9Infections and InfestationsBronchitis2.32Nasopharyngitis2.82.1Musculoskeletal and Connective Tissue DisordersArthralgia2.11.8Myalgia2.21.6Pain in Extremity4.12.7Nervous System DisordersDizziness3.93.5Syncope2.42.2Respiratory DisordersDyspnoea Exertional2.82.4Vascular DisordersHypertension5.84.2Intermittent Claudication2.32.1. 6.2 Clinical Studies Experience in Pediatric Patients. In patients aged 18 years, efficacy and safety have not been studied for treatment periods longer than years.In two open-label, uncontrolled studies, 66 boys and 48 girls with heterozygous familial hypercholesterolemia (9 to 16 years of age, 80% Caucasian, 19% Other [mixed ethnicity], 1% Asians) were treated with fluvastatin sodium administered as fluvastatin capsules 20 mg to 40 mg twice daily, or fluvastatin 80 mg extended-release tablet [see and Clinical Studies (14.2) Use in Specific Populations (8.4) 6.3 Post-Marketing Experience. Because adverse reactions from spontaneous reports are reported voluntarily from population of uncertain size, it is generally not possible to reliably estimate their frequency or establish causal relationship to drug exposure. The following effects have been reported with drugs in this class. Not all the effects listed below have necessarily been associated with fluvastatin sodium therapy.muscle cramps, myalgia, myopathy, rhabdomyolysis, arthralgias, muscle spasms, muscle weakness, myositis. Musculoskeletal: There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see Warnings and Precautions (5.1) dysfunction of certain cranial nerves (including alteration of taste, impairment of extra-ocular movement, facial paresis), tremor, dizziness, vertigo, paresthesia, hypoesthesia, dysesthesia, peripheral neuropathy, peripheral nerve palsy. Neurological: There have been rare post-marketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (one day to years) and symptom resolution (median of weeks).anxiety, insomnia, depression, psychic disturbances. Psychiatric: An apparent hypersensitivity syndrome has been reported rarely which has included one or more of the following features: anaphylaxis, angioedema, lupus erythematosus-like syndrome, polymyalgia rheumatica, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR (erythrocyte sedimentation rate) increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity reaction, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome. Hypersensitivity Reactions: pancreatitis, hepatitis, including chronic active hepatitis, cholestatic jaundice, fatty change in liver, cirrhosis, fulminant hepatic necrosis, hepatoma, anorexia, vomiting, fatal and non-fatal hepatic failure. Gastrointestinal: rash, dermatitis, including bullous dermatitis, eczema, alopecia, pruritus, variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails). Skin: gynecomastia, loss of libido, erectile dysfunction. Reproductive: progression of cataracts (lens opacities), ophthalmoplegia. Eye: elevated transaminases, alkaline phosphatase, gamma-glutamyl transpeptidase and bilirubin; thyroid function abnormalities. Laboratory Abnormalities:.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. 2-year study was performed in rats at dose levels of 6, 9, and 18 to 24 (escalated after one year) mg/kg/day. These treatment levels represented plasma drug levels of approximately 9, 13, and 26 to 35 times the mean human plasma drug concentration after 40 mg oral dose. low incidence of forestomach squamous papillomas and one carcinoma of the forestomach at the 24 mg/kg/day dose level was considered to reflect the prolonged hyperplasia induced by direct contact exposure to fluvastatin sodium rather than to systemic effect of the drug. In addition, an increased incidence of thyroid follicular cell adenomas and carcinomas was recorded for males treated with 18 to 24 mg/kg/day. The increased incidence of thyroid follicular cell neoplasm in male rats with fluvastatin sodium appears to be consistent with findings from other HMG-CoA reductase inhibitors. In contrast to other HMG-CoA reductase inhibitors, no hepatic adenomas or carcinomas were observed.The carcinogenicity study conducted in mice at dose levels of 0.3, 15 and 30 mg/kg/day revealed, as in rats, statistically significant increase in forestomach squamous cell papillomas in males and females at 30 mg/kg/day and in females at 15 mg/kg/day. These treatment levels represented plasma drug levels of approximately 0.05, 2, and times the mean human plasma drug concentration after 40 mg oral dose.No evidence of mutagenicity was observed with or without rat-liver metabolic activation, in the following studies: microbial mutagen tests using mutant strains of or malignant transformation assay in BALB/3T3 cells; unscheduled DNA synthesis in rat primary hepatocytes; chromosomal aberrations in V79 Chinese Hamster cells; HGPRT V79 Chinese Hamster cells. In addition, there was no evidence of mutagenicity in either rat or mouse micronucleus test. in vitro Salmonella typhimurium Escherichia coli in vivo In study in rats at dose levels for females of 0.6, and mg/kg/day and at dose levels for males of 2, 10 and 20 mg/kg/day, fluvastatin sodium had no adverse effects on the fertility or reproductive performance.Seminal vesicles and testes were small in hamsters treated for months at 20 mg/kg/day (approximately times the 40 mg human daily dose based on surface area, mg/m ). There was tubular degeneration and aspermatogenesis in testes as well as vesiculitis of seminal vesicles. Vesiculitis of seminal vesicles and edema of the testes were also seen in rats treated for years at 18 mg/kg/day (approximately times the human achieved with 40 mg daily dose). max Fluvastatin sodium produced delays in skeletal development in rats at doses of 12 mg/kg/day and in rabbits at doses of 10 mg/kg/day. Malaligned thoracic vertebrae were seen in rats at 36 mg/kg, dose that produced maternal toxicity. These doses resulted in times (rat at 12 mg/kg) or times (rabbit at 10 mg/kg) the 40 mg human exposure based on mg/m surface area. study in which female rats were dosed during the third trimester at 12 and 24 mg/kg/day resulted in maternal mortality at or near term and postpartum. In addition, fetal and neonatal lethality were apparent. No effects on the dam or fetus occurred at mg/kg/day. second study at levels of 2, 6, 12 and 24 mg/kg/day confirmed the findings in the first study with neonatal mortality beginning at mg/kg. modified Segment III study was performed at dose levels of 12 or 24 mg/kg/day with or without the presence of concurrent supplementation with mevalonic acid, product of HMG-CoA reductase which is essential for cholesterol biosynthesis. The concurrent administration of mevalonic acid completely prevented the maternal and neonatal mortality but did not prevent low body weights in pups at 24 mg/kg on days and postpartum.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Fluvastatin is competitive inhibitor of HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) to mevalonate, precursor of sterols, including cholesterol. The inhibition of cholesterol biosynthesis reduces the cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors and thereby increases the uptake of LDL particles. The end result of these biochemical processes is reduction of the plasma cholesterol concentration.. 12.3 Pharmacokinetics. Absorption. Following oral administration of the capsule, fluvastatin reaches peak concentrations in less than one hour. The absolute bioavailability is 24% (range 9% to 50%) after administration of 10 mg dose.At steady-state, administration of fluvastatin with the evening meal results in 50% decrease in , an 11% decrease in AUC, and more than 2-fold increase in as compared to administration hours after the evening meal. No significant differences in the lipid-lowering effects were observed between the two administrations. After single or multiple doses above 20 mg, fluvastatin exhibits saturable first-pass metabolism resulting in more than dose proportional plasma fluvastatin concentrations. max max Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately hours under fasting conditions, after low fat meal, or 2.5 hours after low fat meal. The mean relative bioavailability of the extended-release tablet is approximately 29% (range: 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions. Administration of high fat meal delayed the absorption (t 6h) and increased the bioavailability of the extended-release tablet by approximately 50%. However, the maximum concentration of fluvastatin sodium extended-release tablets seen after high fat meal is less than the peak concentration following single dose or twice daily dose of the 40 mg fluvastatin capsule. max Distribution. Fluvastatin is 98% bound to plasma proteins. The mean volume of distribution (VD is estimated at 0.35 L/kg. At therapeutic concentrations, the protein binding of fluvastatin is not affected by warfarin, salicylic acid and glyburide. ss Metabolism. Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Fluvastatin has two enantiomers. Both enantiomers of fluvastatin are metabolized in similar manner.data indicate that fluvastatin metabolism involves multiple Cytochrome P450 (CYP) isozymes. CYP2C9 isoenzyme is primarily involved in the metabolism of fluvastatin (approximately 75%), while CYP2C8 and CYP3A4 isoenzymes are involved to much less extent, i.e., approximately 5% and approximately 20%, respectively. In vitro Excretion. Following oral administration, fluvastatin is primarily (about 90%) excreted in the feces as metabolites, with less than 2% present as unchanged drug. Approximately 5% of radiolabeled oral dose were recovered in urine. The elimination half-life (t of fluvastatin is approximately hours. 1/2 Specific Populations. Renal Impairment. In patients with moderate to severe renal impairment (CL 10 to 40 mL/min), AUC and increased approximately 1.2-fold after administration of single dose of 40 mg fluvastatin compared to healthy volunteers. In patients with end-stage renal disease on hemodialysis, the AUC increased by approximately 1.5-fold. Fluvastatin sodium extended-release tablets were not evaluated in patients with renal impairment. However, systemic exposures after administration of fluvastatin sodium extended-release tablets are lower than after the 40 mg immediate-release capsule. Cr max Hepatic Impairment. In patients with hepatic impairment due to liver cirrhosis, fluvastatin AUC and increased approximately 2.5-fold compared to healthy subjects after administration of single 40 mg dose. The enantiomer ratios of the two isomers of fluvastatin in hepatic impairment patients were comparable to those observed in healthy subjects. max Geriatric. Plasma levels of fluvastatin are not significantly different in patients age 65 years compared to patients age 21 to 49 years.. Gender. In study evaluating the effect of age and gender on fluvastatin pharmacokinetics, there were no significant differences in fluvastatin exposures between males and females, except between younger females and younger males (both ages 21 to 49 years), where there was an approximate 30% increase in AUC in females. Adjusting for body weight decreases the magnitude of the differences seen.. Pediatric. Pharmacokinetic data in the pediatric population are not available.. Drug-Drug Interactions. Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.The below listed drug interaction information is derived from studies using fluvastatin capsules.Table 3: Effect of Coadministered Drugs on Fluvastatin Systemic ExposureCoadministered drug and dosing regimenFluvastatinDose (mg)Single dose unless otherwise notedChange in AUCMean ratio (with/without coadministered drug and no change 1-fold) or change (with/without coadministered drug and no change 0%); symbols of and indicate the exposure increase and decrease, respectively.Change in max Cyclosporine stable dose (b.i.d) Considered clinically significant [see and Dosage and Administration (2) Drug Interactions (7) 20 mg QD for 14 weeks 90% 30%Fluconazole 400 mg QD day 1, 200 mg b.i.d day to 40 mg QD 84% 44%Cholestyramine g QD20 mg QD administered hrs after meal plus cholestyramine 51% 83%Rifampicin 600 mg QD for days20 mg QD 53% 42%Cimetidine 400 mg b.i.d for days, QD on day 620 mg QD 30% 40%Ranitidine 150 mg b.i.d. for days, QD on day 620 mg QD 10% 50%Omeprazole 40 mg QD for days20 mg QD 20% 37%Phenytoin 300 mg QD40 mg b.i.d for days 40% 27%Propranolol 40 mg b.i.d for 3.5 days40 mg QD 5%No changeDigoxin 0.1 mg to 0.5 mg QD for weeks40 mg QDNo change 11%Diclofenac 25 mg QD40 mg QD for days 50% 80%Glyburide mg to 20 mg QD for 22 days40 mg b.i.d for 14 days 51% 44%Warfarin 30 mg QD40 mg QD for days 30% 67%Clopidogrel 300 mg loading dose on day 10, 75 mg QD on days 11 to 1980 mg XL QD for 19 days 2% 27% Data from drug-drug interaction studies involving fluvastatin and coadministration of either gemfibrozil, tolbutamide or losartan indicate that the PK disposition of either gemfibrozil, tolbutamide or losartan is not significantly altered when coadministered with fluvastatin.Table 4: Effect of Fluvastatin Coadministration on Systemic Exposure of Other DrugsFluvastatin dosage regimenCoadministered drugName and Dose (mg)Single dose unless otherwise notedChange in AUCMean ratio (with/without coadministered drug and no change 1-fold) or change (with/without coadministered drug and no change 0%); symbols of and indicate the exposure increase and decrease, respectively.Change in max 40 mg QD for daysPhenytoin 300 mg QD Considered clinically significant [see and Dosage and Administration (2) Drug Interactions (7) 20% 5%40 mg b.i.d for 21 daysGlyburide mg to 20 mg QD for 22 days 70% 50%40 mg QD for daysDiclofenac 25 mg QD 25% 60%40 mg QD for daysWarfarin 30 mg QDS-warfarin: 7%R-warfarin: no changeS-warfarin: 10%R-warfarin: 6%.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.1 Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia. In 12 placebo-controlled studies in patients with primary hypercholesterolemia and mixed dyslipidemia, fluvastatin was administered to 1,621 patients in daily dose regimens of 20 mg, 40 mg, and 80 mg (40 mg twice daily) for at least weeks duration (Table 5). After 24 weeks of treatment, treatment with fluvastatin resulted in significantly reduced plasma LDL-C, TC, TG, and Apo compared to placebo and was associated with variable increases in HDL-C across the dose range.In patients with primary mixed dyslipidemia as defined by baseline plasma TG levels >= 200 mg/dL and 400 mg/dL, treatment with fluvastatin produced significant decreases in Total-C, LDL-C, TG and Apo and variable increases in HDL-C (Table 5).Table 5: Median Percent Change in Lipid Parameters from Baseline to Week 24 Endpoint All Placebo-Controlled Studies (Fluvastatin Capsules)Total CholTGLDLApo BHDLDoseN% N% N% N% N% All Patients Fluvastatin Capsules 20 mg Data for fluvastatin capsules from 12 placebo-controlled trials. 747-17747-12747-22114-19747+3 Fluvastatin Capsules 40 mg 748-19748-14748-25125-18748+4 Fluvastatin Capsules 40 mg twice daily 257-27257-18257-36232-28257+6Baseline TG >= 200 mg/dL Fluvastatin Capsules 20 mg 148-16148-17148-2223-19148+6 Fluvastatin Capsules 40 mg 179-18179-20179-2447-18179+7 Fluvastatin Capsules 40 mg twice daily 76-2776-2376-3569-2876+9. 14.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients. Fluvastatin was studied in two open-label, uncontrolled, dose-titration studies. The first study enrolled 29 pre-pubertal boys, to 12 years of age, who had an LDL-C level 90th percentile for age and one parent with primary hypercholesterolemia and either family history of premature ischemic heart disease or tendon xanthomas. The mean baseline LDL-C was 226 mg/dL (range: 137 to 354 mg/dL). All patients were started on fluvastatin capsules 20 mg daily with dose adjustments every weeks to 40 mg daily then 80 mg daily (40 mg bid) to achieve an LDL-C goal between 96.7 to 123.7 mg/dL. Endpoint analyses were performed at Year 2. Fluvastatin decreased plasma levels of Total-C and LDL-C by 21% and 27%, respectively. The mean achieved LDL-C was 161 mg/dL (range: 74 to 336 mg/dL).The second study enrolled 85 male and female patients, 10 to 16 years of age, who had an LDL-C 190 mg/dL or LDL-C 160 mg/dL and one or more risk factors for coronary heart disease, or LDL-C 160 mg/dL and proven LDL-receptor defect. The mean baseline LDL-C was 225 mg/dL (range: 148 to 343 mg/dL). All patients were started on fluvastatin capsules 20 mg daily with dose adjustments every weeks to 40 mg daily then 80 mg daily (fluvastatin sodium 80 mg extended-release tablet) to achieve an LDL-C goal of 130 mg/dL. Endpoint analyses were performed at Week 114. Fluvastatin decreased plasma levels of Total-C and LDL-C by 22% and 28%, respectively. The mean achieved LDL-C was 159 mg/dL (range: 90 to 295 mg/dL).The majority of patients in both studies (83% in the first study and 89% in the second study) were titrated to the maximum daily dose of 80 mg. At study endpoint, 26% to 30% of patients in both studies achieved targeted LDL-C goal of 130 mg/dL. The long-term efficacy of fluvastatin capsules therapy in childhood to reduce morbidity and mortality in adulthood has not been established.. 14.3 Secondary Prevention of Cardiovascular Disease. In the Fluvastatin Capsules Intervention Prevention Study, the effect of fluvastatin capsules 40 mg administered twice daily on the risk of recurrent cardiac events (time to first occurrence of cardiac death, nonfatal myocardial infarction, or revascularization) was assessed in 1,677 patients with CHD who had undergone percutaneous coronary intervention (PCI) procedure (mean time from PCI to randomization 3 days). In this multicenter, randomized, double-blind, placebo-controlled study, patients were treated with dietary/lifestyle counseling and either fluvastatin capsules 40 mg (n 844) or placebo (n 833) given twice daily for median of 3.9 years. The study population was 84% male, 98% Caucasian, with 37% 65 years of age. Mean baseline lipid concentrations were: total cholesterol 201 mg/dL, LDL-C 132 mg/dL, triglycerides 70 mg/dL and HDL-C 39 mg/dL.Fluvastatin capsules significantly reduced the risk of recurrent cardiac events (Figure 1) by 22% (p 0.013, 181 patients in the fluvastatin capsules group vs. 222 patients in the placebo group). Revascularization procedures comprised the majority of the initial recurrent cardiac events (143 revascularization procedures in the fluvastatin capsules group and 171 in the placebo group). Consistent trends in risk reduction were observed in patients 65 years of age.Figure 1: Primary Endpoint Recurrent Cardiac Events (Cardiac Death, Nonfatal MI or Revascularization Procedure) (ITT Population)Outcome data for the Fluvastatin Capsules Intervention Prevention Study are shown in Figure 2. After exclusion of revascularization procedures (CABG and repeat PCI) occurring within the first months of the initial procedure involving the originally instrumental site, treatment with fluvastatin capsules was associated with 32% (p 0.002) reduction in risk of late revascularization procedures (CABG or PCI occurring at the original site 6 months after the initial procedure, or at another site).Figure 2: Fluvastatin Capsules Intervention Prevention Study Primary and Secondary EndpointsIn the Lipoprotein and Coronary Atherosclerosis Study (LCAS), the effect of fluvastatin capsules therapy on coronary atherosclerosis was assessed by quantitative coronary angiography (QCA) in patients with CAD and mild to moderate hypercholesterolemia (baseline LDL-C range 115 to 190 mg/dL). In this randomized double-blind, placebo- controlled trial, 429 patients were treated with conventional measures (Step AHA Diet) and either fluvastatin capsules 40 mg/day or placebo. In order to provide treatment to patients receiving placebo with LDL-C levels >= 160 mg/dL at baseline, adjunctive therapy with cholestyramine was added after Week 12 to all patients in the study with baseline LDL-C values of >= 160 mg/dL which were present in 25% of the study population. Quantitative coronary angiograms were evaluated at baseline and 2.5 years in 340 (79%) angiographic evaluable patients.Compared to placebo, fluvastatin capsules significantly slowed the progression of coronary atherosclerosis as measured by within-patient per-lesion change in minimum lumen diameter (MLD), the primary endpoint (Figure below), percent diameter stenosis (Figure 4), and the formation of new lesions (13% of all fluvastatin patients vs. 22% of all placebo patients). significant difference in favor of fluvastatin capsules was found between all fluvastatin and all placebo patients in the distribution among the three categories of definite progression, definite regression, and mixed or no change. Beneficial angiographic results (change in MLD) were independent of patients gender and consistent across range of baseline LDL-C levels.Figure 3: Change in Minimum Lumen Diameter (mm)Figure 4: Change in Diameter Stenosis. Figure 1: Primary Endpoint Recurrent Cardiac Events (Cardiac Death, Nonfatal MI or Revascularization Procedure) (ITT Population). Figure 2: Fluvastatin Capsules Intervention Prevention Study Primary and Secondary Endpoints. Figure 3: Change in Minimum Lumen Diameter (mm). Figure 4: Change in Diameter Stenosis.

SPL UNCLASSIFIED SECTION.

1.1 Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia. Fluvastatin capsules are indicated:as an adjunct to diet to reduce elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). as an adjunct to diet to reduce Total-C, LDL-C, and Apo levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present: LDL-C remains >= 190 mg/dL or LDL-C remains >= 160 mg/dL and: there is positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present The NCEP classification of cholesterol levels in pediatric patients with familial history of hypercholesterolemia or premature CVD is summarized below.CategoryTotal-C (mg/dL)LDL-C (mg/dL)Acceptable< 170< 110Borderline170 to 199110 to 129High>= 200>= 130Children treated with fluvastatin in adolescence should be reevaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals.. as an adjunct to diet to reduce elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). . as an adjunct to diet to reduce Total-C, LDL-C, and Apo levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present: LDL-C remains >= 190 mg/dL or LDL-C remains >= 160 mg/dL and: there is positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present . LDL-C remains >= 190 mg/dL or . LDL-C remains >= 160 mg/dL and: there is positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present . there is positive family history of premature cardiovascular disease or . two or more other cardiovascular disease risk factors are present.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Dose range: 20 mg to 80 mg/day. ) 2.1 Fluvastatin capsules can be taken with or without food. Do not open fluvastatin capsules prior to administration. ) 2.1 Adults: the recommended starting dose is 40 mg to 80 mg (administered as one fluvastatin 40 mg capsule twice daily). ) 2.2 Do not take two fluvastatin 40 mg capsules at one time. Children with heterozygous familial hypercholesterolemia (ages 10 to 16, inclusive): the recommended starting dose is fluvastatin capsule 20 mg once daily. ) 2.3 Dose range: 20 mg to 80 mg/day. ) 2.1 Fluvastatin capsules can be taken with or without food. . Do not open fluvastatin capsules prior to administration. ) 2.1 Adults: the recommended starting dose is 40 mg to 80 mg (administered as one fluvastatin 40 mg capsule twice daily). ) 2.2 Do not take two fluvastatin 40 mg capsules at one time. . Children with heterozygous familial hypercholesterolemia (ages 10 to 16, inclusive): the recommended starting dose is fluvastatin capsule 20 mg once daily. ) 2.3 2.1 General Dosing Information. Dose range: 20 mg to 80 mg/day.Fluvastatin capsules can be administered orally as single dose, with or without food.Do not open fluvastatin capsules prior to administration.Do not take two fluvastatin 40 mg capsules at one time.Since the maximal effect of given dose is seen within weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patients response to therapy and established treatment guidelines.For patients requiring LDL-C reduction to goal of >= 25%, the recommended starting dose is 40 mg as one capsule in the evening, or 80 mg in divided doses of the 40 mg capsule given twice daily. For patients requiring LDL-C reduction to goal of 25% starting dose of 20 mg may be used.. 2.2 Adult Patients with Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia. Adult patients can be started on fluvastatin capsules. The recommended starting dose for fluvastatin capsules is one 40 mg capsule in the evening, or one fluvastatin 40 mg capsule twice daily. Do not take two fluvastatin 40 mg capsules at one time.. 2.3 Pediatric Patients (10 to 16 Years of Age) with Heterozygous Familial Hypercholesterolemia. The recommended starting dose is one 20 mg fluvastatin capsule. Dose adjustments, up to maximum daily dose administered as fluvastatin capsules 40 mg twice daily should be made at week intervals. Doses should be individualized according to the goal of therapy. [See NCEP Pediatric Panel Guidelines and .] Clinical Studies (14) National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. 89(3):495-501. 1992. Pediatrics. 2.4 Use with Cyclosporine. Do not exceed dose of 20 mg BID fluvastatin capsules in patients taking cyclosporine [see Drug Interactions (7.1) 2.5 Use with Fluconazole. Do not exceed dose of 20 mg BID fluvastatin capsules in patients taking fluconazole [see Drug Interactions (7.2).

DRUG INTERACTIONS SECTION.

7 DRUG INTERACTIONS. Combination increases fluvastatin exposure. Limit fluvastatin capsules dose to 20 mg. , o Cyclosporine: 2.4 7.1 Combination increases fluvastatin exposure. Limit fluvastatin capsules dose to 20 mg. , o Fluconazole: 2.5 7.2 Use with fibrates or lipid-modifying doses (>= g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with fluvastatin. , ) Concomitant Lipid-Lowering Therapies: 5.1 7.3 7.4 Monitor blood glucose levels when fluvastatin dose is changed. ) Glyburide: Monitor plasma phenytoin levels when fluvastatin treatment is initiated or when the dosage is changed. ) Phenytoin: Monitor prothrombin times when fluvastatin coadministration is initiated, discontinued, or the dosage changed. ) Warfarin and Coumarin Derivatives: . Combination increases fluvastatin exposure. Limit fluvastatin capsules dose to 20 mg. , o Cyclosporine: 2.4 7.1 Combination increases fluvastatin exposure. Limit fluvastatin capsules dose to 20 mg. , o Fluconazole: 2.5 7.2 Use with fibrates or lipid-modifying doses (>= g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with fluvastatin. , ) Concomitant Lipid-Lowering Therapies: 5.1 7.3 7.4 Monitor blood glucose levels when fluvastatin dose is changed. ) Glyburide: . Monitor plasma phenytoin levels when fluvastatin treatment is initiated or when the dosage is changed. ) Phenytoin: . Monitor prothrombin times when fluvastatin coadministration is initiated, discontinued, or the dosage changed. ) Warfarin and Coumarin Derivatives: . 7.1 Cyclosporine. Cyclosporine coadministration increases fluvastatin exposure. Therefore, in patients taking cyclosporine, therapy should be limited to fluvastatin capsules 20 mg twice daily. and [See Warnings and Precautions (5.1) .] Clinical Pharmacology (12.3) 7.2 Fluconazole. Administration of fluvastatin 40 mg single dose to healthy volunteers pre-treated with fluconazole for days results in an increase of fluvastatin exposure. Therefore, in patients taking fluconazole, therapy should be limited to fluvastatin capsules 20 mg twice daily. [See .] Clinical Pharmacology (12.3) 7.3 Gemfibrozil. Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of fluvastatin with gemfibrozil should be avoided.. 7.4 Other Fibrates. Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, fluvastatin should be administered with caution when used concomitantly with other fibrates. [See and .] Warnings and Precautions (5.1) Clinical Pharmacology (12.3) 7.5 Niacin. The risk of skeletal muscle effects may be enhanced when fluvastatin is used in combination with lipid-modifying doses (>= g/day) of niacin; reduction in fluvastatin dosage should be considered in this setting. [See .] Warnings and Precautions (5.1) 7.6 Glyburide. Concomitant administration of fluvastatin and glyburide increased glyburide exposures. Patients on concomitant therapy of glyburide and fluvastatin should continue to be monitored appropriately. [See .] Clinical Pharmacology (12.3) 7.7 Phenytoin. Concomitant administration of fluvastatin and phenytoin increased phenytoin exposures. Patients should continue to be monitored appropriately when fluvastatin therapy is initiated or when fluvastatin dose is changed. [See .] Clinical Pharmacology (12.3) 7.8 Warfarin. Bleeding and/or increased prothrombin times have been reported in patients taking coumarin anticoagulants concomitantly with other HMG-CoA reductase inhibitors. Therefore, patients receiving warfarin-type anticoagulants should have their prothrombin times closely monitored when fluvastatin sodium is initiated or the dosage of fluvastatin sodium is changed.. 7.9 Colchicine. Cases of myopathy, including rhabdomyolysis, have been reported with fluvastatin coadministered with colchicine, and caution should be exercised when prescribing fluvastatin with colchicine.

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate.. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to:Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ) 1.1 Reduce elevated TC, LDL-C, and Apo levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ) 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ) 1.2 Slow the progression of atherosclerosis in patients with CHD ) 1.2 Limitations of Use:Fluvastatin capsules have not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). ) 1.3 Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ) 1.1 Reduce elevated TC, LDL-C, and Apo levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ) 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ) 1.2 Slow the progression of atherosclerosis in patients with CHD ) 1.2 Fluvastatin capsules have not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). ) 1.3 1.1 Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia. Fluvastatin capsules are indicated:as an adjunct to diet to reduce elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). as an adjunct to diet to reduce Total-C, LDL-C, and Apo levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present: LDL-C remains >= 190 mg/dL or LDL-C remains >= 160 mg/dL and: there is positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present The NCEP classification of cholesterol levels in pediatric patients with familial history of hypercholesterolemia or premature CVD is summarized below.CategoryTotal-C (mg/dL)LDL-C (mg/dL)Acceptable< 170< 110Borderline170 to 199110 to 129High>= 200>= 130Children treated with fluvastatin in adolescence should be reevaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals.. as an adjunct to diet to reduce elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). . as an adjunct to diet to reduce Total-C, LDL-C, and Apo levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present: LDL-C remains >= 190 mg/dL or LDL-C remains >= 160 mg/dL and: there is positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present . LDL-C remains >= 190 mg/dL or . LDL-C remains >= 160 mg/dL and: there is positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present . there is positive family history of premature cardiovascular disease or . two or more other cardiovascular disease risk factors are present . 1.2 Secondary Prevention of Cardiovascular Disease. In patients with clinically evident CHD, fluvastatin capsules are indicated to:reduce the risk of undergoing coronary revascularization procedures slow the progression of coronary atherosclerosis . reduce the risk of undergoing coronary revascularization procedures . slow the progression of coronary atherosclerosis . 1.3 Limitations of Use. Fluvastatin capsules have not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V).

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy. Teratogenic Effects. Pregnancy Category X. Fluvastatin is contraindicated in women who are or may become pregnant. [See .] Contraindications (4) Lipid lowering drugs are contraindicated during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Serum cholesterol and triglycerides increase during normal pregnancy. Atherosclerosis is chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy.There are no adequate and well controlled studies of use with fluvastatin during pregnancy. Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In review of about 100 prospectively followed pregnancies in women exposed to other statins, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed the rate expected in the general population. The number of cases is adequate only to exclude 3- to 4-fold increase in congenital anomalies over background incidence. In 89% of prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Teratology studies with fluvastatin in rats and rabbits showed maternal toxicity at high dose levels, but there was no evidence of embryotoxic or teratogenic potential [see Non-Clinical Toxicology (13) Fluvastatin should be administered to women of child-bearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If woman becomes pregnant while taking fluvastatin capsules, the drug should be discontinued and the patient advised again as to the potential hazards to the fetus.. 8.3 Nursing Mothers. Based on animal data, fluvastatin is present in breast milk in 2:1 ratio (milk:plasma). Because of the potential for serious adverse reactions in nursing infants, nursing women should not take fluvastatin. [See .] Contraindications (4) 8.4 Pediatric Use. The safety and efficacy of fluvastatin in children and adolescent patients to 16 years of age with heterozygous familial hypercholesterolemia have been evaluated in open-label, uncontrolled clinical trials for duration of years. The most common adverse events observed were influenza and infections. In these limited uncontrolled studies, there was no detectable effect on growth or sexual maturation in the adolescent boys or on menstrual cycle length in girls. Adolescent females should be counseled on appropriate contraceptive methods while on fluvastatin therapy. [See and .] Clinical Studies (14.2) Adverse Reactions (6.3) Dosage and Administration (2.2) [See .] Contraindications (4) 8.5 Geriatric Use. Fluvastatin exposures were not significantly different between the nonelderly and elderly populations (age >= 65 years). Since advanced age (>= 65 years) is predisposing factor for myopathy, fluvastatin should be prescribed with caution in the elderly. [See .] Clinical Pharmacology (12.3) 8.6 Hepatic Impairment. Fluvastatin is contraindicated in patients with active liver disease or unexplained, persistent elevations in serum transaminases. [See .] Clinical Pharmacology (12.3) 8.7 Renal Impairment. Dose adjustments for mild to moderate renal impairment are not necessary. Fluvastatin has not been studied at doses greater than 40 mg in patients with severe renal impairment; therefore, caution should be exercised when treating such patients at higher doses. [See .] Clinical Pharmacology (12.3).

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Risks increase with advanced age (>= 65), uncontrolled hypothyroidism, renal impairment, and combination use with cyclosporine or gemfibrozil. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness and discontinue fluvastatin if myopathy is diagnosed or suspected. , ) Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): 5.1 8.5 8.7 Patients should be advised to report promptly any symptoms of myopathy. Fluvastatin therapy should be discontinued if myopathy is diagnosed or suspected. ) 5.1 Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. ) Liver enzyme abnormalities: 5.2 Risks increase with advanced age (>= 65), uncontrolled hypothyroidism, renal impairment, and combination use with cyclosporine or gemfibrozil. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness and discontinue fluvastatin if myopathy is diagnosed or suspected. , ) Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): 5.1 8.5 8.7 Patients should be advised to report promptly any symptoms of myopathy. Fluvastatin therapy should be discontinued if myopathy is diagnosed or suspected. ) 5.1 Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. ) Liver enzyme abnormalities: 5.2 5.1 Skeletal Muscle. Rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with fluvastatin and other drugs in this class.Fluvastatin capsules should be prescribed with caution in patients with predisposing factors for myopathy. These factors include advanced age (> 65 years), renal impairment, and inadequately treated hypothyroidism.The risk of myopathy and/or rhabdomyolysis with statins is increased with concurrent therapy with cyclosporine, erythromycin, fibrates or niacin. Myopathy was not observed in clinical trial in 74 patients involving patients who were treated with fluvastatin together with niacin. Isolated cases of myopathy have been reported during post-marketing experience with concomitant administration of fluvastatin and colchicine. No information is available on the pharmacokinetic interaction between fluvastatin and colchicine.Uncomplicated myalgia has also been reported in fluvastatin-treated patients In clinical trials, uncomplicated myalgia has been observed infrequently in patients treated with fluvastatin at rates indistinguishable from placebo. Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in CPK values to greater than 10 times the upper limit of normal, was 0.1% in fluvastatin clinical trials. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. [see Adverse Reactions (6) There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents.All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing fluvastatin.Fluvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Fluvastatin therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of renal failure secondary to rhabdomyolysis, e.g., sepsis; hypotension; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy.. 5.2 Liver Enzymes. Increases in serum transaminases (aspartate aminotransferase [AST]/serum glutamic-oxaloacetic transaminase, or alanine aminotransferase [ALT]/serum glutamic-pyruvic transaminase) have been reported with HMG-CoA reductase inhibitors, including fluvastatin. In most cases, the elevations were transient and resolved or improved on continued therapy or after brief interruption in therapy.Approximately 1.1% of patients treated with fluvastatin capsules in worldwide trials developed dose related, persistent elevations of serum transaminase levels to more than times the upper limit of normal. Fourteen of these patients (0.6%) were discontinued from therapy. In all clinical trials, total of 33/2,969 patients (1.1%) had persistent transaminase elevations with an average fluvastatin exposure of approximately 71.2 weeks; 19 of these patients (0.6%) were discontinued. The majority of patients with these abnormal biochemical findings were asymptomatic.In pooled analysis of all placebo-controlled studies in which fluvastatin capsules were used, persistent transaminase elevations (> times the upper limit of normal [ULN] on two consecutive weekly measurements) occurred in 0.2%, 1.5%, and 2.7% of patients treated with daily doses of 20 mg, 40 mg, and 80 mg (titrated to 40 mg twice daily) fluvastatin capsules, respectively. Ninety-one percent of the cases of persistent liver function test abnormalities (20 of 22 patients) occurred within 12 weeks of therapy and in all patients with persistent liver function test abnormalities there was an abnormal liver function test present at baseline or by Week 8.In the pooled analysis of the 24-week controlled trials, persistent transaminase elevation occurred in 1.8% and 4.9% of patients treated with fluvastatin capsules 40 mg and fluvastatin capsules 40 mg twice daily, respectively.It is recommended that liver enzyme tests be performed prior to the initiation of fluvastatin, and if signs or symptoms of liver injury occur.There have been rare post-marketing reports of fatal and non-fatal hepatic failure in patients taking statins, including fluvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with fluvastatin, promptly interrupt therapy. If an alternate etiology is not found do not restart fluvastatin.In very rare cases, possibly drug-related hepatitis was observed that resolved upon discontinuation of treatment. Active liver disease or unexplained serum transaminase elevations are contraindications to the use of fluvastatin capsules. Caution should be exercised when fluvastatin is administered to patients with history of liver disease or heavy alcohol ingestion Such patients should be closely monitored. [See and .] Contraindications (4) Warnings and Precautions (5.2) [see Clinical Pharmacology (12.3) 5.3 Endocrine Effects. Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including fluvastatin.Statins interfere with cholesterol synthesis and lower circulating cholesterol levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production.Fluvastatin exhibited no effect upon non-stimulated cortisol levels and demonstrated no effect upon thyroid metabolism as assessed by measurement of thyroid stimulating hormone (TSH). Small declines in total serum testosterone have been noted in treated groups, but no commensurate elevation in LH occurred, suggesting that the observation was not due to direct effect upon testosterone production. No effect upon FSH in males was noted. Due to the limited number of premenopausal females studied to date, no conclusions regarding the effect of fluvastatin upon female sex hormones may be made.Two clinical studies in patients receiving fluvastatin at doses up to 80 mg daily for periods of 24 to 28 weeks demonstrated no effect of treatment upon the adrenal response to ACTH stimulation. clinical study evaluated the effect of fluvastatin at doses up to 80 mg daily for 28 weeks upon the gonadal response to HCG stimulation. Although the mean total testosterone response was significantly reduced (p 0.05) relative to baseline in the 80 mg group, it was not significant in comparison to the changes noted in groups receiving either 40 mg of fluvastatin or placebo.Patients treated with fluvastatin who develop clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should be exercised if statin or other agent used to lower cholesterol levels is administered to patients receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels of endogenous steroid hormones.. 5.4 CNS Toxicity. CNS effects, as evidenced by decreased activity, ataxia, loss of righting reflex, and ptosis were seen in the following animal studies: the 18-month mouse carcinogenicity study at 50 mg/kg/day, the 6-month dog study at 36 mg/kg/day, the 6-month hamster study at 40 mg/kg/day, and in acute, high dose studies in rats and hamsters (50 mg/kg), rabbits (300 mg/kg) and mice (1500 mg/kg). CNS toxicity in the acute high dose studies was characterized (in mice) by conspicuous vacuolation in the ventral white columns of the spinal cord at dose of 5000 mg/kg and (in rats) by edema with separation of myelinated fibers of the ventral spinal tracts and sciatic nerve at dose of 1500 mg/kg. CNS toxicity, characterized by periaxonal vacuolation, was observed in the medulla of dogs that died after treatment for weeks with 48 mg/kg/day; this finding was not observed in the remaining dogs when the dose level was lowered to 36 mg/kg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this drug class. No CNS lesions have been observed after chronic treatment for up to years with fluvastatin in the mouse (at doses up to 350 mg/kg/day), rat (up to 24 mg/kg/day), or dog (up to 16 mg/kg/day).Prominent bilateral posterior suture lines in the ocular lens were seen in dogs after treatment with 1, 8, and 16 mg/kg/day for years.

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Patients taking fluvastatin should be advised that high cholesterol is chronic condition and they should adhere to their medication along with their National Cholesterol Education Program (NCEP)-recommended diet, regular exercise program, and periodic testing of fasting lipid panel to determine goal attainment. Information for Patients: Patients should be advised about substances they should not take concomitantly with fluvastatin Patients should also be advised to inform other healthcare professionals prescribing new medication that they are taking fluvastatin. [see ]. Warnings and Precautions (5.1) 17.1 Muscle Pain. Patients starting therapy with fluvastatin should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever or if these muscle signs or symptoms persist after discontinuing fluvastatin.. 17.2 Liver Enzymes. It is recommended that liver enzyme tests be performed before the initiation of fluvastatin and if signs or symptoms of liver injury occur. All patients treated with fluvastatin should be advised to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.. 17.3 Pregnancy. Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using fluvastatin. Discuss future pregnancy plans with your patients, and discuss when to stop taking fluvastatin if they are trying to conceive. Patients should be advised that if they become pregnant they should stop taking fluvastatin and call their healthcare professional.. 17.4 Breast-Feeding. Women who are breast-feeding should not use fluvastatin. Patients who have lipid disorder and are breast-feeding should be advised to discuss the options with their healthcare professional.FDA-Approved Patient Labeling.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. 2-year study was performed in rats at dose levels of 6, 9, and 18 to 24 (escalated after one year) mg/kg/day. These treatment levels represented plasma drug levels of approximately 9, 13, and 26 to 35 times the mean human plasma drug concentration after 40 mg oral dose. low incidence of forestomach squamous papillomas and one carcinoma of the forestomach at the 24 mg/kg/day dose level was considered to reflect the prolonged hyperplasia induced by direct contact exposure to fluvastatin sodium rather than to systemic effect of the drug. In addition, an increased incidence of thyroid follicular cell adenomas and carcinomas was recorded for males treated with 18 to 24 mg/kg/day. The increased incidence of thyroid follicular cell neoplasm in male rats with fluvastatin sodium appears to be consistent with findings from other HMG-CoA reductase inhibitors. In contrast to other HMG-CoA reductase inhibitors, no hepatic adenomas or carcinomas were observed.The carcinogenicity study conducted in mice at dose levels of 0.3, 15 and 30 mg/kg/day revealed, as in rats, statistically significant increase in forestomach squamous cell papillomas in males and females at 30 mg/kg/day and in females at 15 mg/kg/day. These treatment levels represented plasma drug levels of approximately 0.05, 2, and times the mean human plasma drug concentration after 40 mg oral dose.No evidence of mutagenicity was observed with or without rat-liver metabolic activation, in the following studies: microbial mutagen tests using mutant strains of or malignant transformation assay in BALB/3T3 cells; unscheduled DNA synthesis in rat primary hepatocytes; chromosomal aberrations in V79 Chinese Hamster cells; HGPRT V79 Chinese Hamster cells. In addition, there was no evidence of mutagenicity in either rat or mouse micronucleus test. in vitro Salmonella typhimurium Escherichia coli in vivo In study in rats at dose levels for females of 0.6, and mg/kg/day and at dose levels for males of 2, 10 and 20 mg/kg/day, fluvastatin sodium had no adverse effects on the fertility or reproductive performance.Seminal vesicles and testes were small in hamsters treated for months at 20 mg/kg/day (approximately times the 40 mg human daily dose based on surface area, mg/m ). There was tubular degeneration and aspermatogenesis in testes as well as vesiculitis of seminal vesicles. Vesiculitis of seminal vesicles and edema of the testes were also seen in rats treated for years at 18 mg/kg/day (approximately times the human achieved with 40 mg daily dose). max Fluvastatin sodium produced delays in skeletal development in rats at doses of 12 mg/kg/day and in rabbits at doses of 10 mg/kg/day. Malaligned thoracic vertebrae were seen in rats at 36 mg/kg, dose that produced maternal toxicity. These doses resulted in times (rat at 12 mg/kg) or times (rabbit at 10 mg/kg) the 40 mg human exposure based on mg/m surface area. study in which female rats were dosed during the third trimester at 12 and 24 mg/kg/day resulted in maternal mortality at or near term and postpartum. In addition, fetal and neonatal lethality were apparent. No effects on the dam or fetus occurred at mg/kg/day. second study at levels of 2, 6, 12 and 24 mg/kg/day confirmed the findings in the first study with neonatal mortality beginning at mg/kg. modified Segment III study was performed at dose levels of 12 or 24 mg/kg/day with or without the presence of concurrent supplementation with mevalonic acid, product of HMG-CoA reductase which is essential for cholesterol biosynthesis. The concurrent administration of mevalonic acid completely prevented the maternal and neonatal mortality but did not prevent low body weights in pups at 24 mg/kg on days and postpartum.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. Absorption. Following oral administration of the capsule, fluvastatin reaches peak concentrations in less than one hour. The absolute bioavailability is 24% (range 9% to 50%) after administration of 10 mg dose.At steady-state, administration of fluvastatin with the evening meal results in 50% decrease in , an 11% decrease in AUC, and more than 2-fold increase in as compared to administration hours after the evening meal. No significant differences in the lipid-lowering effects were observed between the two administrations. After single or multiple doses above 20 mg, fluvastatin exhibits saturable first-pass metabolism resulting in more than dose proportional plasma fluvastatin concentrations. max max Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately hours under fasting conditions, after low fat meal, or 2.5 hours after low fat meal. The mean relative bioavailability of the extended-release tablet is approximately 29% (range: 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions. Administration of high fat meal delayed the absorption (t 6h) and increased the bioavailability of the extended-release tablet by approximately 50%. However, the maximum concentration of fluvastatin sodium extended-release tablets seen after high fat meal is less than the peak concentration following single dose or twice daily dose of the 40 mg fluvastatin capsule. max Distribution. Fluvastatin is 98% bound to plasma proteins. The mean volume of distribution (VD is estimated at 0.35 L/kg. At therapeutic concentrations, the protein binding of fluvastatin is not affected by warfarin, salicylic acid and glyburide. ss Metabolism. Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Fluvastatin has two enantiomers. Both enantiomers of fluvastatin are metabolized in similar manner.data indicate that fluvastatin metabolism involves multiple Cytochrome P450 (CYP) isozymes. CYP2C9 isoenzyme is primarily involved in the metabolism of fluvastatin (approximately 75%), while CYP2C8 and CYP3A4 isoenzymes are involved to much less extent, i.e., approximately 5% and approximately 20%, respectively. In vitro Excretion. Following oral administration, fluvastatin is primarily (about 90%) excreted in the feces as metabolites, with less than 2% present as unchanged drug. Approximately 5% of radiolabeled oral dose were recovered in urine. The elimination half-life (t of fluvastatin is approximately hours. 1/2 Specific Populations. Renal Impairment. In patients with moderate to severe renal impairment (CL 10 to 40 mL/min), AUC and increased approximately 1.2-fold after administration of single dose of 40 mg fluvastatin compared to healthy volunteers. In patients with end-stage renal disease on hemodialysis, the AUC increased by approximately 1.5-fold. Fluvastatin sodium extended-release tablets were not evaluated in patients with renal impairment. However, systemic exposures after administration of fluvastatin sodium extended-release tablets are lower than after the 40 mg immediate-release capsule. Cr max Hepatic Impairment. In patients with hepatic impairment due to liver cirrhosis, fluvastatin AUC and increased approximately 2.5-fold compared to healthy subjects after administration of single 40 mg dose. The enantiomer ratios of the two isomers of fluvastatin in hepatic impairment patients were comparable to those observed in healthy subjects. max Geriatric. Plasma levels of fluvastatin are not significantly different in patients age 65 years compared to patients age 21 to 49 years.. Gender. In study evaluating the effect of age and gender on fluvastatin pharmacokinetics, there were no significant differences in fluvastatin exposures between males and females, except between younger females and younger males (both ages 21 to 49 years), where there was an approximate 30% increase in AUC in females. Adjusting for body weight decreases the magnitude of the differences seen.. Pediatric. Pharmacokinetic data in the pediatric population are not available.. Drug-Drug Interactions. Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.The below listed drug interaction information is derived from studies using fluvastatin capsules.Table 3: Effect of Coadministered Drugs on Fluvastatin Systemic ExposureCoadministered drug and dosing regimenFluvastatinDose (mg)Single dose unless otherwise notedChange in AUCMean ratio (with/without coadministered drug and no change 1-fold) or change (with/without coadministered drug and no change 0%); symbols of and indicate the exposure increase and decrease, respectively.Change in max Cyclosporine stable dose (b.i.d) Considered clinically significant [see and Dosage and Administration (2) Drug Interactions (7) 20 mg QD for 14 weeks 90% 30%Fluconazole 400 mg QD day 1, 200 mg b.i.d day to 40 mg QD 84% 44%Cholestyramine g QD20 mg QD administered hrs after meal plus cholestyramine 51% 83%Rifampicin 600 mg QD for days20 mg QD 53% 42%Cimetidine 400 mg b.i.d for days, QD on day 620 mg QD 30% 40%Ranitidine 150 mg b.i.d. for days, QD on day 620 mg QD 10% 50%Omeprazole 40 mg QD for days20 mg QD 20% 37%Phenytoin 300 mg QD40 mg b.i.d for days 40% 27%Propranolol 40 mg b.i.d for 3.5 days40 mg QD 5%No changeDigoxin 0.1 mg to 0.5 mg QD for weeks40 mg QDNo change 11%Diclofenac 25 mg QD40 mg QD for days 50% 80%Glyburide mg to 20 mg QD for 22 days40 mg b.i.d for 14 days 51% 44%Warfarin 30 mg QD40 mg QD for days 30% 67%Clopidogrel 300 mg loading dose on day 10, 75 mg QD on days 11 to 1980 mg XL QD for 19 days 2% 27% Data from drug-drug interaction studies involving fluvastatin and coadministration of either gemfibrozil, tolbutamide or losartan indicate that the PK disposition of either gemfibrozil, tolbutamide or losartan is not significantly altered when coadministered with fluvastatin.Table 4: Effect of Fluvastatin Coadministration on Systemic Exposure of Other DrugsFluvastatin dosage regimenCoadministered drugName and Dose (mg)Single dose unless otherwise notedChange in AUCMean ratio (with/without coadministered drug and no change 1-fold) or change (with/without coadministered drug and no change 0%); symbols of and indicate the exposure increase and decrease, respectively.Change in max 40 mg QD for daysPhenytoin 300 mg QD Considered clinically significant [see and Dosage and Administration (2) Drug Interactions (7) 20% 5%40 mg b.i.d for 21 daysGlyburide mg to 20 mg QD for 22 days 70% 50%40 mg QD for daysDiclofenac 25 mg QD 25% 60%40 mg QD for daysWarfarin 30 mg QDS-warfarin: 7%R-warfarin: no changeS-warfarin: 10%R-warfarin: 6%.